New targets for lymphoma treatment

Annals of Oncology

Volumn 19, Issue SUPPL. 4, 2008, Pages

  Johnson, P W M ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INHIBITOR; B LYMPHOCYTE RECEPTOR; BORTEZOMIB; CARFILZOMIB; EVEROLIMUS; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; ISOSORBIDE; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; OBATOCLAX; PROTEASOME; PROTEASOME INHIBITOR; RITUXIMAB; ROMIDEPSIN; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; VORINOSTAT; YM 155; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; GOSSYPOL; GOSSYPOL ACETIC ACID; HEAT SHOCK PROTEIN; MONOCLONAL ANTIBODY; PROTEIN KINASE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BONE MARROW SUPPRESSION; CELL SURFACE; CLINICAL TRIAL; CONTINUOUS INFUSION; CUTANEOUS T CELL LYMPHOMA; DRUG TARGETING; ENZYME INHIBITION; FATIGUE; GENE REPRESSION; HUMAN; IMMUNOMODULATION; LYMPHOMA; MANTLE CELL LYMPHOMA; MYELOID LEUKEMIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK FACTOR; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; CLASSIFICATION; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS, PHASE II AS TOPIC; ENZYME INHIBITORS; GOSSYPOL; HEAT-SHOCK PROTEINS; HISTONE DEACETYLASES; HUMANS; IMMUNOTHERAPY; LYMPHOMA; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASES; RECEPTORS, TUMOR NECROSIS FACTOR; THALIDOMIDE; TREATMENT OUTCOME; TUMOR NECROSIS FACTORS;

EID: 48149112664     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn198     Document Type: Article

References (15)

1. Cragg MS, Morgan SM, Chan HT et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003; 101: 1045-1052.
2. Zhu D, McCarthy H, Ottensmeier CH, Johnson P, Hamblin TJ, Stevenson FK. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood 2002; 99: 2562-2568.
3. Costa LJ. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treatment Rev 2007; 33: 78-84.
4. Witzig TE, Geyer SM, Ghobrial I et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347-5356.
5. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861-1874.
6. Lenz G, Davis RE, Ngo VN et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319: 1676-1679.
7. Lam LT, Wright G. Davis RE et al. Cooperative signaling through the STAT3 and NF-{kappa}B pathways in subtypes of diffuse large B cell lymphoma. Blood 2008.
8. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev 2006; 5: 769-784.
9. Peart MJ, Smyth GK, van Laar RK et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102: 3697-3702.
10. Duvic M, Talpur R, Ni X et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31-39.
11. Younes A, Pro B, Fanale M et al. Isotype-selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin lymphoma. Blood 2007; 110: 2566.
12. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005; 23: 630-639.
13. Strauss SJ, Maharaj L, Hoare S et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 200; 24: 2105-2112.
14. Velculescu VE, Madden SL, Zhang L et al. Analysis of human transcriptomes. Nat Genet 1999; 23: 387-388.
15. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008; 26: 1544-1552.